Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more

Location: 628 Middlefield Road, Palo Alto, CA, 94301, United States | Website: https://kalaristx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

92.2M

52 Wk Range

$2.14 - $24.15

Previous Close

$4.93

Open

$4.91

Volume

76,609

Day Range

$4.74 - $5.00

Enterprise Value

139.9M

Cash

88.43M

Avg Qtr Burn

-8.04M

Insider Ownership

14.29%

Institutional Own.

69.90%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TH103 Details Neovascular Age-Related Macular Degeneration	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.